Will a Trastuzumab Biosimilar Work in Early HER2+ Breast Cancer?
The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 20, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer Trastuzumab Biosimilar on Par With Reference Product in Early Breast Cancer
Safety, efficacy and clinical outcomes were similar for Amgen's trastuzumab biosimilar ABP 980 and the trastuzumab reference product in women with HER2-positive early breast cancer in the LILAC study, researchers reported June 4 at the 2018 ASCO Annual Meeting.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Tucatinib Shows Promise in Phase I Study of HER2-Positive Breast Cancer
The HER2 TKI tucatinib plus capecitabine or trastuzumab were reasonably well tolerated and showed antitumor activity in a phase I trial of HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Many Breast Cancer Patients Can Safely Skip Chemo, Major Study Finds
CHICAGO (CBS News/AP) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk. The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs. “The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most wo...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 4, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Breast Cancer Chemotherapy Source Type: news

NCI-MATCH precision medicine clinical trial releases new findings
(ECOG-ACRIN Cancer Research Group) The released data is from three treatment arms, all single-arm phase 2 studies: the drug taselisib in patients with mutations in the PIK3CA gene (Arm I); the drug ado-trastuzumab emtansine (T-DM1) in patients with HER2-overexpressing tumors (Arm Q); and the drug AZD4547 in patients with mutations in the FGFR pathway (Arm W). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2018 Category: Cancer & Oncology Source Type: news

Most Women With Breast Cancer Can Skip Chemo, According to New Study
(CHICAGO) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk. The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs. “The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most women in this ...
Source: TIME: Health - June 3, 2018 Category: Consumer Health News Authors: Marilynn Marchione / AP Tags: Uncategorized healthytime onetime Women's Health Source Type: news

Most Women With Breast Cancer Can Skip Chemo, According to New Study
(CHICAGO) — Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient’s risk. The study is the largest ever done of breast cancer treatment, and the results are expected to spare up to 70,000 patients a year in the United States and many more elsewhere the ordeal and expense of these drugs. “The impact is tremendous,” said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in New York. Most women in this ...
Source: TIME: Science - June 3, 2018 Category: Science Authors: Marilynn Marchione / AP Tags: Uncategorized healthytime onetime Women's Health Source Type: news

European Commission approves Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced that the European Commission (EC) has approved Perjeta ® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - June 1, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced that the European Commission (EC) has approved Perjeta ® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2018 Category: Pharmaceuticals Source Type: news

Trastuzumab for 6 Months Instead of 1 Year? Trastuzumab for 6 Months Instead of 1 Year?
The standard of care for HER2-positive breast cancer is trastuzumab (Herceptin) for a year; but could half that be enough?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Trastuzumab Emtansine in HER2 Metastatic Breast Cancer Trastuzumab Emtansine in HER2 Metastatic Breast Cancer
Recent survival results lead some to question the optimal sequence for trastuzumab emtansine in metastatic breast cancer.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Breast cancer treatment time could be HALVED
British research from the University of Warwick and the University of Cambridge has revealed the amount of time a person needs on herceptin could be halved from 12 months to six (stock). (Source: the Mail online | Health)
Source: the Mail online | Health - May 17, 2018 Category: Consumer Health News Source Type: news

Nigeria:Roche Launches Innovative Medicine Against Breast Cancer in Nigeria
[This Day] Swiss multinational, Roche has launched the subcutaneous formulation of Herceptin, its flagship breast cancer drug in Nigeria. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 17, 2018 Category: African Health Source Type: news

Shorter-Duration Trastuzumab as Effective for HER2+ Early Breast Cancer
Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial. (Source: CancerNetwork)
Source: CancerNetwork - May 17, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Breast Cancer Patients May Shorten Herceptin Regimen: Study
Title: Breast Cancer Patients May Shorten Herceptin Regimen: StudyCategory: Health NewsCreated: 5/16/2018 12:00:00 AMLast Editorial Review: 5/17/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 17, 2018 Category: Cancer & Oncology Source Type: news

Good News on Early Breast Cancer: Herceptin Treatment Can Be Shortened
A large, new study shows that the treatment regimen, typically recommended for a year, can be just as effective at 6 months, reducing serious side effects and costs. (Source: NYT Health)
Source: NYT Health - May 16, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Breast Cancer Herceptin (Drug) Genentech Inc Earl, Helena M side effects Source Type: news

Breast Cancer Patients May Shorten Herceptin Regimen: Study
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 16, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, News, Source Type: news

Six Months of Trastuzumab Equal to 12 in Breast Ca
(MedPage Today) -- Similar outcomes and less cardiotoxicity, but more research needed (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - May 16, 2018 Category: OBGYN Source Type: news

Test of Herceptin Finds Briefer Treatment Might Work, With Fewer Side Effects
(Source: NPR Health and Science)
Source: NPR Health and Science - May 16, 2018 Category: Consumer Health News Authors: Richard Harris Source Type: news

Test of Herceptin Finds Briefer Treatment Can Work, With Fewer Side Effects
(Source: NPR Health and Science)
Source: NPR Health and Science - May 16, 2018 Category: Consumer Health News Authors: Richard Harris Source Type: news

Roche breast cancer drug treatment time can be halved - study
(Reuters) - Treating early stage breast cancer patients for just six months with Roche's Herceptin works as well as the current 12-month regimen, researchers who conducted a large clinical trial said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Shorter drug treatment OK for many breast cancer patients
New research suggests that many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug instead of the usual 12 (Source: ABC News: Health)
Source: ABC News: Health - May 16, 2018 Category: Consumer Health News Tags: Health Source Type: news

For Women With Early Breast Cancer, Herceptin Treatment Can Be Much Shorter
A large, new study shows that the treatment regimen, typically recommended for a year, can be just as effective at 6 months, reducing serious side effects and costs. (Source: NYT Health)
Source: NYT Health - May 16, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Breast Cancer Herceptin (Drug) American Society of Clinical Oncology Cambridge University side effects Genentech Inc Source Type: news

Breast Cancer Patients May Shorten Herceptin Regimen: Study
WEDNESDAY, May 16, 2018 -- For years, the drug Herceptin has helped women with an aggressive form of breast cancer beat the disease. But there's one downside: In a minority of cases, the drug can trigger heart damage. Now, a new study finds that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 16, 2018 Category: General Medicine Source Type: news

Shorter trastuzumab treatment for HER2+ breast cancer can be as effective, with fewer cardiac side-effects
(American Society of Clinical Oncology) A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four years was 89.4 percent with 6 months of therapy and 89.8 percent with 12 months of therapy. In addition, only 4 percent of women in the 6-month arm stopped trastuzumab early because of cardiac problems, compared with 8 percent in the 12-month arm. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2018 Category: International Medicine & Public Health Source Type: news

CHMP recommends EU approval of Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast c ancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - April 27, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast c ancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - April 27, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast c ancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - April 27, 2018 Category: Pharmaceuticals Source Type: news

FDA Declines to Approve Pfizer Biosimilar of Roche's Cancer Drug FDA Declines to Approve Pfizer Biosimilar of Roche's Cancer Drug
Pfizer Inc said on Monday U.S. regulators declined to approve the company ’ s biosimilar of Roche ’ s blockbuster treatment for breast cancer, Herceptin, and sought additional technical information.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 25, 2018 Category: Consumer Health News Tags: Pharmacist News Source Type: news

FDA declines to approve Pfizer biosimilar of Roche's cancer drug
(Reuters) - Pfizer Inc said on Monday U.S. regulators declined to approve the company's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, and sought additional technical information. (Source: Reuters: Health)
Source: Reuters: Health - April 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA declines to approve Pfizer's biosimilar to Roche's cancer drug
(Reuters) - Pfizer Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve the company's biosimilar to Roche's breast cancer drug, Herceptin, and sought additional technical information. (Source: Reuters: Health)
Source: Reuters: Health - April 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer
WEDNESDAY, April 18, 2018 -- For patients with human epidermal growth factor receptor 2 (HER2)/neu-positive uterine serous carcinoma, adding intravenous trastuzumab to treatment with carboplatin-paclitaxel is associated with increased... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2018 Category: Pharmaceuticals Source Type: news

Trastuzumab Effective in Uterine Serous Carcinoma (CME/CE)
(MedPage Today) -- In patients overexpressing HER2, a 5-month boost in PFS when added to carboplatin-paclitaxel (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 14, 2018 Category: Hematology Source Type: news

New drug combo improves survival of women with rare uterine cancer
(Johns Hopkins Medicine) Adding the monoclonal antibody drug trastuzumab -- already used to treat certain breast cancers -- to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2018 Category: Cancer & Oncology Source Type: news

Poly-ligand Profiling May Best Predict Response to Trastuzumab Poly-ligand Profiling May Best Predict Response to Trastuzumab
Poly-ligand profiling (PLP), a proprietary technology platform, has the potential to improve patient stratification for trastuzumab by predicting responders more accurately than standard testing, according to a proof-of-concept study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 5, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Does Trastuzumab Plus Carbo/Paclitaxel Up PFS in Advanced HER2+ Uterine Carcinoma?
At SGO 2018, an early study showed ‘encouraging’ PFS with trastuzumab added to combination carboplatin/paclitaxel for advanced HER2/neu-overexpressing uterine serous carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Gynecologic Cancers News Conferences/SGO Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin(R)) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer THOUSAND OAKS, Calif., March 23, 2018 -- (Healthcare Sales &... Biopharmaceuticals, Oncology, Regulatory Amgen, Allergan, biosimilar, Herceptin, trastuzumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news

Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Data featured in Nature Communications showed ADAPT Biotargeting System significantly out-performed industry standard HER2 testing IRVING, Texas, March 23, 2018 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences®, a leading innovator ... Biopharmaceuticals, Diagnostics, Oncology Caris Life Sciences, ADAPT Biotargeting System, trastuzumab, Herceptin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2018 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin ®) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin® (trastuzumab). ABP 980 has been recommended for approval for the treatment of the same three types of...
Source: Amgen News Release - March 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Lisinopril and Carvedilol Reduce Cardiotoxicity in HER2+ Breast Cancer
Lisinopril and carvedilol reduced cardiotoxicity in patients with HER2-positive breast cancer treated with trastuzumab and anthracyclines. (Source: CancerNetwork)
Source: CancerNetwork - March 13, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Cutting Chemo Heart Risks for Breast Cancer Patients
MONDAY, March 12, 2018 -- Two classes of blood pressure drugs show promise in preventing heart complications caused by chemotherapy for breast cancer, researchers report. One in four women who receives the chemo drug Herceptin develops potentially... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 12, 2018 Category: General Medicine Source Type: news

Popular heart medications can prevent herceptin-induced heart issues in some patients
(American College of Cardiology) Breast cancer patients who started taking one of two well-known heart medications at the same time they initiated trastuzumab -- a targeted cancer therapy that has been linked to heart damage -- received no benefit in terms of preventing declines in heart function, according to research presented at the American College of Cardiology's 67th Annual Scientific Session. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2018 Category: Cancer & Oncology Source Type: news

Drug copies ready to take next bite out of Roche's cancer sales
LONDON (Reuters) - European oncologists will soon get their hands on cut-price copies of breast cancer drug Herceptin, turning the screws on maker Roche and giving another boost to a new breed of companies focused on so-called biosimilars. (Source: Reuters: Health)
Source: Reuters: Health - February 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Trastuzumab Biosimilar Equivalent in Early HER2+ Breast CA Tx (CME/CE)
(MedPage Today) -- Ratio of breast pathologic complete response rate 10% higher with SB3 (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 7, 2018 Category: Hematology Source Type: news

Trastuzumab: No negative impact on cardiac function
(NRG Oncology) Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negatively affect cardiac function in women with node-positive, human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer who survive without cancer recurrence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 3, 2018 Category: International Medicine & Public Health Source Type: news

Ganetespib, Paclitaxel, Trastuzumab for HER2+ Breast Cancer Ganetespib, Paclitaxel, Trastuzumab for HER2+ Breast Cancer
Early research finds that ganetespib added to paclitaxel and trastuzumab shows promise for heavily pretreated patients with HER2+ breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Mylan breast cancer drug approved in Brazil
Mylan NV on Friday said it had received the green light in Brazil for a treatment for breast cancer that it developed with a partner in the country. Biocon LTD (BSE: BIOCON) and Mylan (Nasdaq: MYL) co-developed biosimilar Trastuzumab, which treats overexpressing HER2-positive metastatic breast cancer, HER2-positive early stage breast cancer and HER2-positive advanced gastric cancer. It will be sold in Brazil in Brazil as Zedora by Libbs Farmac eutica. "The approval of Zedora, Brazil's first Trastuzumab… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 29, 2017 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Mylan-Biocon's breast cancer biosimilar gets ANVISA nod
Biosimilar trastuzumab, indicated for breast cancer treatment, has been co-developed by Biocon and Mylan. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 29, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - December 21, 2017 Category: Pharmaceuticals Source Type: news